# US 2024/0190919 A1 · Peptide compounds and therapeutic uses of same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0190919 A1 - Document ID: US20240190919A1 - Status: Published application - Kind: A1 - Application number: 18/586,715 - Filed: 2024-02-26 - Published: 2024-06-13 - Earliest claimed: 2018-07-11 - Assignees: Immunity Pharma Ltd. - Applicants: Immunity Pharma Ltd. - Inventors: Eran OVADIA; Avi BEN-SHIMON - Web page: https://patentgrep.com/patent/US20240190919A1 ## CPC - C07K 7/06: having 5 to 11 amino acids - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof. ## Claims ### Claim 1 An isolated peptide being no longer than ten amino acids which comprises an amino acid sequence as set forth in SEQ ID NOs: 3, 4, 7, 18 or 20, wherein the peptide is capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse. ### Claim 2 (depends on 1) The isolated peptide of claim 1, consisting of the amino acid sequence as set forth in SEQ ID NOs: 3, 4, 7, 18 or 20. ### Claim 3 (depends on 1) The isolated peptide of claim 1, being 6 or 7 amino acids long. ### Claim 4 (depends on 1) The isolated peptide of claim 1, wherein the peptide is attached to a cell penetrating moiety. ### Claim 5 (depends on 4) The isolated peptide of claim 4, wherein said cell penetrating moiety is attached to an N-terminus of the peptide. ### Claim 6 A method of treating a disease associated with apoptosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of isolated peptide being no longer than ten amino acids which comprises an amino acid sequence as set forth in SEQ ID NOs: 3, 4, 7, 18, 20 or 21, wherein the peptide is capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse, thereby treating the disease associated with apoptosis. ### Claim 7 (depends on 6) The method of claim 6, wherein said disease associated with apoptosis is an inflammatory or degenerative disease. ### Claim 8 (depends on 6) The method of claim 6, wherein said disease is Amyotrophic Lateral Sclerosis (ALS). ### Claim 9 (depends on 6) The method of claim 6, wherein said disease is an autoimmune disease. ### Claim 10 (depends on 7) The method of claim 7, wherein the degenerative disease is a neurodegenerative disease. ### Claim 11 (depends on 6) The method of claim 6, wherein said disease associated with apoptosis is selected from the group consisting of age-related macular degeneration (AMD), retinitis pigmentosa, stroke and myocardial infarction. ### Claim 12 (depends on 1) A pharmaceutical composition comprising the peptide of claim 1 as an active agent and a physiologically acceptable carrier.